239 related articles for article (PubMed ID: 37600808)
21. Activated phosphoinositide 3-kinase delta syndrome 1 and 2 (APDS 1 and APDS 2): similarities and differences based on clinical presentation in two boys.
Ewertowska M; Grześk E; Urbańczyk A; Dąbrowska A; Bąbol-Pokora K; Łęcka M; Kołtan S
Allergy Asthma Clin Immunol; 2020; 16():22. PubMed ID: 32265996
[TBL] [Abstract][Full Text] [Related]
22. ANCA vasculitis expands the spectrum of autoimmune manifestations of activated PI3 kinase δ syndrome.
Sood AK; Francis O; Schworer SA; Johnson SM; Smith BD; Googe PB; Wu EY
Front Pediatr; 2023; 11():1179788. PubMed ID: 37274825
[TBL] [Abstract][Full Text] [Related]
23. Case Report: EBV Chronic Infection and Lymphoproliferation in Four APDS Patients: The Challenge of Proper Characterization, Therapy, and Follow-Up.
Rivalta B; Amodio D; Milito C; Chiriaco M; Di Cesare S; Giancotta C; Conti F; Santilli V; Pacillo L; Cifaldi C; Desimio MG; Doria M; Quinti I; De Vito R; Di Matteo G; Finocchi A; Palma P; Trizzino A; Tommasini A; Cancrini C
Front Pediatr; 2021; 9():703853. PubMed ID: 34540765
[TBL] [Abstract][Full Text] [Related]
24. Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.
Rao VK; Webster S; Dalm VASH; Šedivá A; van Hagen PM; Holland S; Rosenzweig SD; Christ AD; Sloth B; Cabanski M; Joshi AD; de Buck S; Doucet J; Guerini D; Kalis C; Pylvaenaeinen I; Soldermann N; Kashyap A; Uzel G; Lenardo MJ; Patel DD; Lucas CL; Burkhart C
Blood; 2017 Nov; 130(21):2307-2316. PubMed ID: 28972011
[TBL] [Abstract][Full Text] [Related]
25. Activated Phosphoinositide 3-Kinase δ Syndrome: a Large Pediatric Cohort from a Single Center in China.
Qiu L; Wang Y; Tang W; Yang Q; Zeng T; Chen J; Chen X; Zhang L; Zhou L; Zhang Z; An Y; Tang X; Zhao X
J Clin Immunol; 2022 May; 42(4):837-850. PubMed ID: 35296988
[TBL] [Abstract][Full Text] [Related]
26. Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study.
Elkaim E; Neven B; Bruneau J; Mitsui-Sekinaka K; Stanislas A; Heurtier L; Lucas CL; Matthews H; Deau MC; Sharapova S; Curtis J; Reichenbach J; Glastre C; Parry DA; Arumugakani G; McDermott E; Kilic SS; Yamashita M; Moshous D; Lamrini H; Otremba B; Gennery A; Coulter T; Quinti I; Stephan JL; Lougaris V; Brodszki N; Barlogis V; Asano T; Galicier L; Boutboul D; Nonoyama S; Cant A; Imai K; Picard C; Nejentsev S; Molina TJ; Lenardo M; Savic S; Cavazzana M; Fischer A; Durandy A; Kracker S
J Allergy Clin Immunol; 2016 Jul; 138(1):210-218.e9. PubMed ID: 27221134
[TBL] [Abstract][Full Text] [Related]
27. Determining value in the treatment of activated PI3Kδ syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.
Abad MR; Alerany C; Alsina L; Granados EL; Neth O; Poveda JL; Rivière JG; Rodríguez-Gallego C; Tutein Nolthenius JB; Figueiredo R; Labazuy SS; Gil A
Glob Reg Health Technol Assess; 2024; 11():124-130. PubMed ID: 38784663
[TBL] [Abstract][Full Text] [Related]
28. Two cases of successful sirolimus treatment for patients with activated phosphoinositide 3-kinase δ syndrome 1.
Jiang L; Hu X; Lin Q; Chen R; Shen Y; Zhu Y; Xu Q; Li X
Allergy Asthma Clin Immunol; 2023 Sep; 19(1):86. PubMed ID: 37742016
[TBL] [Abstract][Full Text] [Related]
29. Lymphoproliferation in Inborn Errors of Immunity: The Eye Does Not See What the Mind Does Not Know.
Sharma S; Pilania RK; Anjani G; Sudhakar M; Arora K; Tyagi R; Dhaliwal M; Vignesh P; Rawat A; Singh S
Front Immunol; 2022; 13():856601. PubMed ID: 35603189
[TBL] [Abstract][Full Text] [Related]
30. Epstein-Barr Virus Susceptibility in Activated PI3Kδ Syndrome (APDS) Immunodeficiency.
Carpier JM; Lucas CL
Front Immunol; 2017; 8():2005. PubMed ID: 29387064
[TBL] [Abstract][Full Text] [Related]
31. Autoimmune Cytopenia as an Early and Initial Presenting Manifestation in Activated PI3 Kinase Delta Syndrome: Case Report and Review.
Schworer SA; Francis OL; Johnson SM; Smith BD; Gold SH; Smitherman AB; Wu EY
J Pediatr Hematol Oncol; 2021 Nov; 43(8):281-287. PubMed ID: 34054047
[TBL] [Abstract][Full Text] [Related]
32. Future of Therapy for Inborn Errors of Immunity.
Perez E
Clin Rev Allergy Immunol; 2022 Aug; 63(1):75-89. PubMed ID: 35020169
[TBL] [Abstract][Full Text] [Related]
33. Activated PI3Kδ syndrome, an immunodeficiency disorder, leads to sensorimotor deficits recapitulated in a murine model.
Serra I; Manusama OR; Kaiser FMP; Floriano II; Wahl L; van der Zalm C; IJspeert H; van Hagen PM; van Beveren NJM; Arend SM; Okkenhaug K; Pel JJM; Dalm VASH; Badura A
Brain Behav Immun Health; 2021 Dec; 18():100377. PubMed ID: 34786564
[TBL] [Abstract][Full Text] [Related]
34. Natural Course of Activated Phosphoinositide 3-Kinase Delta Syndrome in Childhood and Adolescence.
Bloomfield M; Klocperk A; Zachova R; Milota T; Kanderova V; Sediva A
Front Pediatr; 2021; 9():697706. PubMed ID: 34350147
[TBL] [Abstract][Full Text] [Related]
35. Activated PI3Kinase Delta Syndrome-A Multifaceted Disease.
Thouenon R; Moreno-Corona N; Poggi L; Durandy A; Kracker S
Front Pediatr; 2021; 9():652405. PubMed ID: 34249806
[TBL] [Abstract][Full Text] [Related]
36. Infections in activated PI3K delta syndrome (APDS).
Brodsky NN; Lucas CL
Curr Opin Immunol; 2021 Oct; 72():146-157. PubMed ID: 34052541
[TBL] [Abstract][Full Text] [Related]
37. PI3Kδ and primary immunodeficiencies.
Lucas CL; Chandra A; Nejentsev S; Condliffe AM; Okkenhaug K
Nat Rev Immunol; 2016 Nov; 16(11):702-714. PubMed ID: 27616589
[TBL] [Abstract][Full Text] [Related]
38. Case Report: Hodgkin Lymphoma and Refractory Systemic Lupus Erythematosus Unveil Activated Phosphoinositide 3-Kinase-δ Syndrome 2 in an Adult Patient.
Conti F; Catelli A; Cifaldi C; Leonardi L; Mulè R; Fusconi M; Stefoni V; Chiriaco M; Rivalta B; Di Cesare S; Schifino G; Sbrega F; Di Matteo G; Ferrari S; Cancrini C; Pession A
Front Pediatr; 2021; 9():702546. PubMed ID: 34307262
[No Abstract] [Full Text] [Related]
39. Autoimmune Cytopenias and Dysregulated Immunophenotype Act as Warning Signs of Inborn Errors of Immunity: Results From a Prospective Study.
Schiavo E; Martini B; Attardi E; Consonni F; Ciullini Mannurita S; Coniglio ML; Tellini M; Chiocca E; Fotzi I; Luti L; D'Alba I; Veltroni M; Favre C; Gambineri E
Front Immunol; 2021; 12():790455. PubMed ID: 35058929
[TBL] [Abstract][Full Text] [Related]
40. Autoimmune manifestations among 461 patients with monogenic inborn errors of immunity.
Azizi G; Tavakol M; Yazdani R; Delavari S; Moeini Shad T; Rasouli SE; Jamee M; Pashangzadeh S; Kalantari A; Shariat M; Shafiei A; Mohammadi J; Hassanpour G; Chavoshzadeh Z; Mahdaviani SA; Momen T; Behniafard N; Nabavi M; Bemanian MH; Arshi S; Molatefi R; Sherkat R; Shirkani A; Alyasin S; Jabbari-Azad F; Ghaffari J; Mesdaghi M; Ahanchian H; Khoshkhui M; Eslamian MH; Cheraghi T; Dabbaghzadeh A; Nasiri Kalmarzi R; Esmaeilzadeh H; Tafaroji J; Khalili A; Sadeghi-Shabestari M; Darougar S; Moghtaderi M; Ahmadiafshar A; Shakerian B; Heidarzadeh M; Ghalebaghi B; Fathi SM; Darabi B; Fallahpour M; Mohsenzadeh A; Ebrahimi S; Sharafian S; Vosughimotlagh A; Tafakoridelbari M; Rahimi Haji-Abadi M; Ashournia P; Razaghian A; Rezaei A; Salami F; Shirmast P; Bazargan N; Mamishi S; Khazaei HA; Negahdari B; Shokri S; Nabavizadeh SH; Bazregari S; Ghasemi R; Bayat S; Eshaghi H; Rezaei N; Abolhassani H; Aghamohammadi A
Pediatr Allergy Immunol; 2021 Aug; 32(6):1335-1348. PubMed ID: 33774840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
